(DL)-3-O-Methyldopa

Names

[ Name ]:
(DL)-3-O-Methyldopa

[Synonym ]:
3-Methoxytyrosine
3-Methoxy-D,L-tyrosine
2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid
3-Methoxy-tyrosine
Tyrosine, 3-methoxy-
3-METHOXY-DL-TYROSINE
UNII:SO86T1OB2P
3-O-Methyldopa

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
407.3±45.0 °C at 760 mmHg

[ Molecular Formula ]:
C₁₀H₁₃NO₄

[ Molecular Weight ]:
211.214

[ Flash Point ]:
200.1±28.7 °C

[ Exact Mass ]:
211.084457

[ PSA ]:
92.78000

[ LogP ]:
0.08

[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C

[ Index of Refraction ]:
1.591

MSDS

Safety Information

[ Risk Phrases ]:
22-36/37/38

[ Safety Phrases ]:
22-26-36/37/39

[ RIDADR ]:
NONH for all modes of transport

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

N-[[4-(5-ethyl-1,3-benzoxazol-2-yl)phenyl]carbamothioyl]-4-methoxybenzamide
HYDROGEN CYANIDE
(Z)-2-methoxy-4-((2-methyl-5-oxooxazol-4(5H)-ylidene)methyl)phenyl acetate
Pyruvic acid, (4-hydroxy-3-methoxyphenyl)-, 2-oxime
Acetyleugenol
Pyruvic acid, (4-hydroxy-3-methoxyphenyl)-2-thio-
5-vanillyl-imidazolidine-2,4-dione

DownStream

Articles

Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.

Mov. Disord 26 , 543-546, (2011)

Oxidative stress is influenced by the thiol homeostasis, which determines the redox milieu. One of its components is Cysteinyl-glycine (Cys-Gly) generation, as its metabolic precursor is the free radi...

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Clin. Neuropharmacol. 33(3) , 135-41, (2010)

The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluat...

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

Eur. J. Neurol. 19(6) , 820-6, (2012)

Catechol-O-methyltransferase inhibitors may be used to decrease levodopa requirement. The objective was to investigate whether the levodopa/carbidopa intestinal gel infusion dose can be reduced by 20%...

(R)-3-O-Methyldopa-d3 hydrochloride
(R)-3-O-Methyldopa-d3
(±)-Metanephrine
(+/-)-3-O-benzyl-1,2:4,5-di-O,O-cyclohexylidene-myo-inositol
3-O-Methyldopa D3
DL-3,4-di-O-acetyl-(1,2,4/3,5)-5-bromomethyl-2-(toluene-p-sulfonamido)-1,3,4-cyclohexanetriol